Volume : 11, Issue : 06, June – 2024
Title:
ANALYSIS OF FLUNARIZINE DIHYDROCHLORIDE IN PHARMACEUTICAL DOSAGE FORM BY ULTRAVIOLET SPECTROPHOTOMETRY AND ITS APPLICATION TO DISSOLUTION STUDIES
Authors :
G. Sai Tejaswi, Dr. B. Poornima, Dr. K. Venu Gopal
Abstract :
Flunarizine Dihydrochloride (FNZ) is a selective calcium entry blocker with histamine H1 blocking activity intended for the treatment of migraine, occlusive peripheral vascular disease and as an adjuvant in the therapy of epilepsy. Existing methods analyzed Flunarizine in bulk and pharmaceutical dosage forms either as single component or in binary mixture, its related impurities and its degradation products by chromatographic techniques and spectroscopic techniques including AUC methods. Only fewer techniques to analyze Flunarizine Dihydrochloride have been reported. Hence we focused on analysis of FNZ in its conventional tablet dosage form by UV spectrophotometry. FNZ was estimated in commercial tablets (Flunarin 5) by a simple, accurate, precise and economical validated method. Excellent linearity was established in the concentration range of 3- 15 mcg/ ml at λmax of 253.20 nm using 0.1 M Hydrochloric acid as solvent (R2= 0.9995). The assay results were satisfactory (95.42 ± 0.1%). Precision, recoveries were good and within limits (%RSD < 2.0). LOD and LOQ were 0.2471 mcg and 0.7489 mcg respectively. Further dissolution studies for FNZ tablets were carried out using rotating paddle apparatus with 0.1M Hydrochloric acid as dissolution medium pertaining to the ease of applicability of the developed method. These studies provide scope for analyzing FNZ in different pharmaceutical dosage forms and by varied analytical approaches.
Key words: Flunarizine Dihydrochloride, Method development, Validation, Dissolution.
Cite This Article:
Please cite this article in press G Sai Tejaswi et al Analysis Of Flunarizine Dihydrochloride In Pharmaceutical Dosage Form By Ultraviolet Spectrophotometry And Its Application To Dissolution Studies.,Indo Am. J. P. Sci, 2024; 11 (6).
Number of Downloads : 10
References:
1. Wikipedia, http://www.drugbank.ca/drugs/DB04841.
2. European Pharmacopoeia 5.0, pg.1608-1609.
3. P.Ravisankar, G.Devala Rao and M.Krishna Chaitanya, Development and Validation of an improved RP-HPLC method for the quantitative determination of Flunarizine in bulk and tablet dosage form, Research Journal of pharmaceutical biological and chemical sciences, Vol-4, issue 3,July- sept 2010,pg.no-666-678.
4. Michael Geary, Niamho’connor, Mary Wharton, Paul Sweetman, development and validation of a rapid chromatographic method for the analysis of Flunarizine and its main production impurities, Journal of pharmaceutical analysis 2018;3(3);211-214.
5. Wahbi AA,EI Walily AF, Hassan Em,Saliman FG,El Gendi A, Liquid chromatographic determination of Flunarizine dihydrochloride in the presence of its degradation product, Journal of pharmaceutical and biomedical analysis;1995 May ; 13(6);777-84.
6. Sangita W.Chapke,Madhuri D.Game, UV spectrophotometric method development and validation for simultaneous determination of Flunarizine dihydrochloride and Propranolol hydrochloride in combined capsule dosage form, Asian Journal of Research Chemistry, May 2019, Vol 6, Issue 5,P8.
7. Doshi A.K; Patel, B.N; Patel, C.N; Development and validation of spectrophotometric method for simultaneous determination of propranolol hydrochloride and Flunarizine dihydrochloride in their combined dosage formulation; International Journal of Pharmaceutical Sciences and Research; June 2022,Vol-3,issue 6, P1741.
8. Palak Patil and Kashyap K. bhatt, development and validation of HPTLC method for estimation of Propranolol hydrochloride and Flunarizine dihydrochloride in combined dosage form, International Scholarly Research network ISRN analytical chemistry,vol- 2022,March-April2012,pg.no 1-6.
9. Shivarkar NA, Dudhe PB, Nagras MA, development and validation of a HPTLC method for simultaneous quantitation of Flunarizine dihydrochloride and Propranolol hydrochloride in capsule dosage form, Indian Journal of Pharmaceutical sciences, 2019, May; 75(3); 364-8.
10. Indian Pharmacopoeia 2021, The Indian Pharmacopoeia Commission, Ghaziabad, Volume 1, 559, 587, 611.
11. Validation of Analytical Procedures: Text and Methodology Q2 (R1), ICH Harmonized Tripartite Guideline, Current step 4 version, Parent Guideline dated 27 October 1994.